Find Sofosbuvir manufacturers, exporters & distributors on PharmaCompass

Sovaldi

Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

35 API Suppliers, 9 USDMF, 9 EU WC, 3 KDMF, 7 NDC API, 26 Listed Suppliers, $ API Reference Price

35 API Suppliers
9 USDMF
9 EU WC
3 KDMF
7 NDC API
26 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

INTERMEDIATES

16 Intermediates Suppliers

16 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

41 FDF Dossiers, 14 FDA Orange Book, 6 Europe, 4 Canada, 2 South Africa, 15 Listed Dossiers

41 FDF Dossiers
14 FDA Orange Book
6 Europe
4 Canada
2 South Africa
15 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 13 SPI Pharma, 2 Seqens, 4 DKSH, 1 Jai Radhe Sales, 4 Faran Shimi Pharmaceutical, 2 Boai NKY Pharmaceuticals Ltd, 9 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 12 BASF, 5 Corel Pharma Chem, 5 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 3 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 22 Kerry, 12 Microlex e.U, 2 Nomisma Healthcare, 2 Novo Excipients, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 3 Prachin Chemical, 13 Roquette, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

65 Fillers, Diluents & Binders, 31 Direct Compression, 21 Coating Systems & Additives, 16 Thickeners and Stabilizers, 16 Granulation, 15 Controlled & Modified Release, 15 Co-Processed Excipients, 15 Disintegrants & Superdisintegrants, 14 Lubricants & Glidants, 12 Taste Masking, 11 Chewable & Orodispersible Aids, 9 Topical, 9 Parenteral, 9 Film Formers & Plasticizers, 6 Solubilizers, 3 Coloring Agents, 3 Emulsifying Agents, 3 API Stability Enhancers, 2 Rheology Modifiers

DIGITAL CONTENT

22 DATA COMPILATION #PharmaFlow, 272 NEWS #PharmaBuzz

media
22 DATA COMPILATION #PharmaFlow
272 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 7 Finished Drug Prices, 15 Annual Reports

globalSalesInformation
2 US Medicaid Prescriptions
7 Finished Drug Prices
15 Annual Reports

MARKET PLACE

19 APIs, 1 FDF Dossiers

marketPlace
19 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

358 US Patents, 44 US Exclusivities, 2 Health Canada Patents

patents
358 US Patents
44 US Exclusivities
2 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 Others

otherSolutions
1 Others

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 730

MARKET PLACE

API

FDF

16INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

2DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

358

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

272

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

902,133,726

Annual Reports (USD Million)

29,079

Finished Drug Prices

164 RELATED EXCIPIENT COMPANIES

275EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Psi-7977, 1190307-88-0, Sovaldi, Gs-7977, Psi 7977, Gs7977

Molecular Formula

C₂₂H₂₉FN₃O₉P

Molecular Weight

529.5 g/mol

InChI Key

TTZHDVOVKQGIBA-IQWMDFIBSA-N

FDA UNII

WJ6CA3ZU8B

A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.

Sofosbuvir is a Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor. The mechanism of action of sofosbuvir is as a RNA Replicase Inhibitor.

1 2D Structure

Sofosbuvir

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate

2.1.2 InChI

InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1

2.1.3 InChI Key

TTZHDVOVKQGIBA-IQWMDFIBSA-N

2.1.4 Canonical SMILES

CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3

2.1.5 Isomeric SMILES

C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3

2.2 Other Identifiers

2.2.1 UNII

WJ6CA3ZU8B

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-((5-(2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic Acid Isopropyl Ester

2. 7977, Psi

3. Gs 7977

4. Gs-7977

5. Gs7977

6. Psi 7977

7. Psi-7977

8. Psi7977

9. Sovaldi

2.3.2 Depositor-Supplied Synonyms

1. Psi-7977

2. 1190307-88-0

3. Sovaldi

4. Gs-7977

5. Psi 7977

6. Gs7977

7. Wj6ca3zu8b

8. Propan-2-yl (2s)-2-[[[(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate

9. Chebi:85083

10. Gs 7977

11. L-alanine, N-((p(s),2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl)-, 1-methylethyl Ester

12. Sofosbuvir [usan]

13. Sofosbuvir [usan:inn]

14. Unii-wj6ca3zu8b

15. Hepcinat

16. Hepcvir

17. Resof

18. Sovihep

19. Hsdb 8226

20. Psi7977

21. Sovaldi (tn)

22. Sofosbuvir [mi]

23. Sofosbuvir [inn]

24. Sofosbuvir [jan]

25. Sofosbuvir (jan/usan)

26. Sofosbuvir [vandf]

27. Sofosbuvir(psi-7977)

28. Sofosbuvir (gs-7977)

29. Sofosbuvir [who-dd]

30. 2-((5-(2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic Acid Isopropyl Ester

31. C22h29fn3o9p

32. Gtpl7368

33. Schembl2010114

34. Sofosbuvirpsi7977gs-7977

35. Chembl1259059

36. Sofosbuvir [orange Book]

37. Ammd00019

38. Ex-a389

39. Vosevi Component Sofosbuvir

40. Dtxsid701027632

41. Epclusa Component Sofosbuvir

42. Harvoni Component Sofosbuvir

43. (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate

44. Isopropyl (2s)-2-[[[(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate

45. Mfcd18782704

46. S2794

47. Sofosbuvir Component Of Vosevi

48. Akos024464753

49. Sofosbuvir Component Of Epclusa

50. Sofosbuvir Component Of Harvoni

51. Zinc100074252

52. Am84279

53. Ccg-269909

54. Cs-0554

55. Db08934

56. Gi 7977

57. Gi-7977

58. Sofosbuvir (psi-7977, Gs-7977)

59. Sofosbuvir (psi-7977; Gs-7977)

60. Bs165550

61. Hy-15005

62. Sw219116-1

63. D10366

64. Q2502747

65. (s)-2-{[(1r,4r,5r)-5-(2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-yl)-4-(r)-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy]phenoxyphosphorylamino}propionic Acid (s)-isopropyl Ester

66. (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-h

67. (s)-isopropyl 2-((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

68. Isopropyl ((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-l-alaninate

69. Isopropyl (2s)-2-{[(s)-{[(2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate

70. S)-isopropyl 2-((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4- Dihydropyrimidin-1(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)- (phenoxy)phosphorylamino)propanoate

2.4 Create Date

2010-05-17

3 Chemical and Physical Properties

Molecular Formula	C₂₂H₂₉FN₃O₉P
Molecular Weight	529.5 g/mol
XLogP3	1
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	11
Exact Mass	529.16254467 g/mol
Monoisotopic Mass	529.16254467 g/mol
Topological Polar Surface Area	153 Å²
Heavy Atom Count	36
Formal Charge	0
Complexity	913
Isotope Atom Count	0
Defined Atom Stereocenter Count	6
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Therapeutic Uses

Sovaldi is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen. /Included in US product label/

NIH; DailyMed. Current Medication Information for Sovaldi (Sofosbuvir) Tablet, Film Coated (Revised: November 2014). Available from, as of December 31, 2014: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80beab2c-396e-4a37-a4dc-40fdb62859cf

The following points should be considered when initiating treatment with Sovaldi: Monotherapy of Sovaldi is not recommended for treatment of chronic hepatitis C (CHC). Treatment regimen and duration are dependent on both viral genotype and patient population. Treatment response varies based on baseline host and viral factors.

4.2 Drug Warning

FDA is warning that serious slowing of the heart rate can occur when the antiarrhythmic drug amiodarone is taken together with either the hepatitis C drug Harvoni (ledipasvir/sofosbuvir) or with Sovaldi (sofosbuvir) taken in combination with another direct acting antiviral for the treatment of hepatitis C infection. FDA is adding information about serious slowing of the heart rate, known as symptomatic bradycardia, to the Harvoni and Sovaldi labels. FDA is recommending that health care professionals should not prescribe either Harvoni or Sovaldi combined with another direct acting antiviral, such as the investigational drug daclatasvir or Olysio (simeprevir), with amiodarone. FDA review of submitted postmarketing adverse event reports found that patients can develop a serious and life-threatening symptomatic bradycardia when either Harvoni or Sovaldi combined with another direct-acting antiviral is taken together with amiodarone. The reports included the death of one patient due to cardiac arrest and three patients requiring placement of a pacemaker to regulate their heart rhythms. The other patients recovered after discontinuing either the hepatitis C drugs or amiodarone, or both. The cause of these events could not be determined. FDA will continue to monitor Harvoni and Sovaldi for risks of serious symptomatic bradycardia and further investigate the reason why the use of amiodarone with these hepatitis C drugs led to the heart-related events.

FDA; Safety Alerts for Human Medical Products; Hepatitis C Treatments Containing Sofosbuvir in Combination With Another Direct Acting Antiviral Drug: Drug Safety Communication - Serious Slowing of Heart Rate When Used With Antiarrhythmic Drug Amiodarone (March 24, 2015). Available from, as of March 24, 2015: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm439662.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Concomitant use of sofosbuvir with drugs that are potent inducers of the P-glycoprotein (P-gp) transport system in the intestine (e.g., rifampin, St. John's wort) is not recommended since this may result in substantially decreased sofosbuvir plasma concentrations and could lead to reduced therapeutic effect of sofosbuvir.

American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 799

Anemia has been reported in patients receiving sofosbuvir in conjunction with ribavirin or in conjunction with peginterferon alfa andribavirin. In clinical trials, anemia was reported in 21% of patients who received 12 weeks of treatment with sofosbuvir, peginterferon alfa, and ribavirin compared with 12% of patients who received 24 weeks of treatment with peginterferon alfa and ribavirin without sofosbuvir. In addition, hemoglobin concentrations less than 10 g/dL were reported in 23% of patients who received 12 weeks of treatment with sofosbuvir, peginterferon alfa, and ribavirin compared with 14% of patients who received 24 weeks of treatment with peginterferon alfa and ribavirin without sofosbuvir.

American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 799

Adverse effects reported in more than 20% of patients receiving sofosbuvir in conjunction with ribavirin and peginterferon alfa include fatigue, headache, nausea, insomnia, and anemia.

American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 800

For more Drug Warnings (Complete) data for Sofosbuvir (13 total), please visit the HSDB record page.

4.3 Drug Indication

Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa. When used in combination with [DB09027] as the combination product Harvoni, sofosbuvir has the following indications: treatment of genotypes 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; in combination with [DB00811] for genotype 1 infection with decompensated cirrhosis; or in combination with [DB00811] for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis. When used in combination with [DB11613] as the combination product Epclusa, sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis. Resistance: Reduced susceptibility to sofosbuvir has been associated with the NS5B substitution mutation S282T.

FDA Label

Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 and 5. 1).

For hepatitis C virus (HCV) genotype specific activity, see sections 4. 4 and 5. 1.

Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 and 5. 1).

For hepatitis C virus (HCV) genotype specific activity, see sections 4. 4 and 5. 1.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Sofosbuvir acts against HCV and is categorized as a direct-acting antiviral agent (DAA). At a dose 3 times the recommended dose, sofosbuvir does not prolong QTc to any clinically relevant extent.

5.2 MeSH Pharmacological Classification

Antiviral Agents

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)

5.3 FDA Pharmacological Classification

5.3.1 Active Moiety

SOFOSBUVIR

5.3.2 FDA UNII

WJ6CA3ZU8B

5.3.3 Pharmacological Classes

Nucleoside Analog [EXT]; RNA Replicase Inhibitors [MoA]; Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]

5.4 ATC Code

J05AX15

J - Antiinfectives for systemic use

J05 - Antivirals for systemic use

J05A - Direct acting antivirals

J05AP - Antivirals for treatment of hcv infections

J05AP08 - Sofosbuvir

5.5 Absorption, Distribution and Excretion

Absorption

When given orally, sofosbuvir reaches its maximum plasma concentration in about 0.5 to 2 hours with a maximal concentration (Cmax) of 567 ng/mL.

Route of Elimination

Sofosbuvir is eliminated by three routes: urine ( 80%), feces (14%), and respiration (2.5%); however, elimination through the kidneys is the major route.

Volume of Distribution

The volume of distribution for sofosbuvir has yet to be determined.

Clearance

The clearance of sofosbuvir has yet to be determined.

Sofosbuvir is approximately 61-65% bound to human plasma proteins and the binding is independent of drug concentration over the range of 1 ug/mL to 20 ug/mL. Protein binding of GS-331007 was minimal in human plasma. After a single 400 mg dose of (14)C-sofosbuvir in healthy subjects, the blood to plasma ratio of (14)C-radioactivity was approximately 0.7.

NIH; DailyMed. Current Medication Information for Sovaldi (Sofosbuvir) Tablet, Film Coated (Revised: November 2014). Available from, as of March 17, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80beab2c-396e-4a37-a4dc-40fdb62859cf

The pharmacokinetic properties of sofosbuvir and the predominant circulating metabolite GS-331007 have been evaluated in healthy adult subjects and in subjects with chronic hepatitis C. Following oral administration of SOVALDI, sofosbuvir was absorbed with a peak plasma concentration observed at approximately 0.5-2 hour post-dose, regardless of dose level. Peak plasma concentration of GS-331007 was observed between 2 to 4 hours post-dose. Based on population pharmacokinetic analysis in subjects with genotype 1 to 6 HCV infection who were coadministered ribavirin (with or without pegylated interferon), geometric mean steady state AUC0-24 was 969 ng*hr/mL for sofosbuvir (N=838), and 6790 ng*hr/mL for GS-331007 (N=1695), respectively. Relative to healthy subjects administered sofosbuvir alone (N = 272), the sofosbuvir AUC0-24 was 60% higher; and GS-331007 AUC0-24 was 39% lower, respectively, in HCV-infected subjects. Sofosbuvir and GS-331007 AUCs are near dose proportional over the dose range of 200 mg to 1200 mg.

Following a single 400 mg oral dose of (14)C-sofosbuvir, mean total recovery of the dose was greater than 92%, consisting of approximately 80%, 14%, and 2.5% recovered in urine, feces, and expired air, respectively. The majority of the sofosbuvir dose recovered in urine was GS-331007 (78%) while 3.5% was recovered as sofosbuvir. These data indicate that renal clearance is the major elimination pathway for GS-331007.

Studies in pregnant rats showed that sofosbuvir crossed the placenta. Fetal blood and brain sofosbuvir derived radioactivity was higher than in dams, but fetal liver and kidney had lower levels than corresponding organs in dams. Sofosbuvir-derived radioactivity was also quantifiable in milk from day 2 postpartum rats, but nursing pups did not appear to be extensively exposed to drug-derived radioactivity. Milk to plasma ratios were 0.1 at 1 hour and 0.8 at 24 hours.

European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Sovaldi; p.21 (November 21, 2013). Available from, as of March 17, 2015: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002798/WC500160600.pdf

For more Absorption, Distribution and Excretion (Complete) data for Sofosbuvir (6 total), please visit the HSDB record page.

5.6 Metabolism/Metabolites

In vitro studies in human liver microsomes showed that sofosbuvir was an efficient substrate for Cathepsin A (Cat A) and carboxyl esterase 1 (CES1). Sofosbuvir was cleaved by CatA and CES1 and subsequent activation steps included amino acid removal by histidine triad nucleotide-binding protein 1 (HINT1) and phosphorylation by uridine monophosphate-cytidine monophosphate (UMP-CMP) kinase and nucleoside diphosphate (NDP) kinase. In vitro data indicated that Cat A preferentially hydrolysed sofosbuvir (the S-diastereomer) while CES1 did not exhibit stereoselectivity.

In vitro studies in human liver microsomes showed that sofosbuvir was an efficient substrate for Cathepsin A (Cat A) and carboxyl esterase 1 (CES1). There were no indications of metabolism via urdine diphosphate glucuronosyltransferases (UGTs) or flavin-containing monooxygenase (FMO). Sofosbuvir was cleaved by CatA and CES1 and subsequent activation steps included amino acid removal by histidine triad nucleotide-binding protein 1 (HINT1) and phosphorylation by uridine monophosphate-cytidine monophosphate (UMP-CMP) kinase and nucleoside diphosphate (NDP) kinase. In vitro data indicated that Cat A preferentially hydrolysed sofosbuvir (the S-diastereomer) while CES1 did not exhibit stereoselectivity. This would be consistent with studies using GS-9851 showing a less efficient metabolism to the triphosphate in the hepatically-derived cell line containing the Clone A replicon and shown to exhibit low CES 1 activity, but high Cat A activity compared with primary human hepatocytes. Following incubation of hepatocytes from rat, dog, monkey and human GS-9851 was converted to the triphosphate GS-461203 in all species, most efficiently in human. Sofosbuvir was also readily converted to the triphosphate in dog liver after oral doses and was the dominant metabolite at all time points assessed with a long half-life of approx. 18 hours. The active metabolite GS-461203 could not be detected in monkey. Further while GS-461203 was detected in rat liver, it could not be measured in liver from mouse.

European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Sovaldi; p.21-2 (November 21, 2013). Available from, as of March 17, 2015: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002798/WC500160600.pdf

Sofosbuvir is extensively metabolized in the liver to form the pharmacologically active nucleoside analog triphosphate GS-461203. The metabolic activation pathway involves sequential hydrolysis of the carboxyl ester moiety catalyzed by human cathepsin A (CatA) or carboxylesterase 1 (CES1) and phosphoramidate cleavage by histidine triad nucleotide-binding protein 1 (HINT1) followed by phosphorylation by the pyrimidine nucleotide biosynthesis pathway. Dephosphorylation results in the formation of nucleoside metabolite GS-331007 that cannot be efficiently rephosphorylated and lacks anti-HCV activity in vitro.

GS-331007 and GS-566500 were detected in all species with GS-331007 being the major drug related material in all species and all matrices. In plasma, urine and feces of all species administered sofosbuvir the primary metabolite detected was GS-331007 accounting for >80% of total exposure. In rat liver and plasma GS-566500 was also detected. The metabolite profile was overall comparable between non-pregnant, pregnant and postpartum rats and in milk of postpartum rats with GS-331007 and 2 sulfate conjugates of GS-331007 being the major metabolites.

European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Sovaldi; p.22 (November 21, 2013). Available from, as of March 17, 2015: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002798/WC500160600.pdf

In dog following a single oral dose of 20 mg/kg of sofosbuvir three metabolites in plasma were identified, GS-331007, GS-566500 and M4 (proposed glucuronidation product of GS-606965), accounting for 93.4%, 1.6% and 0.5%, respectively of total plasma AUC. Parent compound amounted to 4.5%. In dog (and mouse) the majority of a radioactive dose was recovered in urine within 8 to 12 hours.

For more Metabolism/Metabolites (Complete) data for Sofosbuvir (7 total), please visit the HSDB record page.

5.7 Biological Half-Life

Sofosbuvir has a terminal half life of 0.4 hours.

The median terminal half-lives of sofosbuvir and GS-331007 were 0.4 and 27 hours, respectively.

5.8 Mechanism of Action

Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Following intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), sofosbuvir incorporates into HCV RNA by the NS5B polymerase and acts as a chain terminator [synthesis, A7533]. More specifically, Sofosbuvir prevents HCV viral replication by binding to the two Mg2+ ions present in HCV NS5B polymerase's GDD active site motif and preventing further replication of HCV genetic material.

Sofosbuvir is a direct-acting antiviral agent (pan-genotypic polymerase inhibitor) against the hepatitis C virus. HCV RNA replication is mediated by a membrane-associated multiprotein replication complex. The HCV polymerase (NS5B protein) is an RNA-dependent RNA polymerase (RdRp). It is the essential initiating and catalytic subunit of this replication complex and is critical for the viral replication cycle. There is no human homolog for HCV NS5B RdRp. Sofosbuvir is a monophosphorylated pyrimidine nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203). GS-461203 competes with natural nucleotides for incorporation (by HCV NS5B) into the nascent RNA strand during replication of the viral genome. GS-461203 differs from endogenous pyrimidine nucleotides in that it has been modified at the 2' position with the addition of a methyl and a fluoro functional group. Incorporation of GS-461203 into nascent RNA strongly reduces the efficiency of further RNA elongation by RdRp, resulting in premature termination of RNA synthesis. The stopping of viral replication leads to a rapid decline of HCV viral load and clearing of HCV levels in the body.

Health Canada; Product Monograph for Sovaldi (Sofosbuvir) Tablets, Drug Identification Number (DIN): 02418355 p.20 (Date of Preparation: December 4, 2014). Available from, as of March 17, 2015: https://webprod5.hc-sc.gc.ca/dpd-bdpp/start-debuter.do?lang=eng

API SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Export","activeIngredients":"SOFOSBUVIR","year":"2021","qtr":"Q2","strtotime":1618425000,"product":"SOFOSBUVIR (FORM VI)","address":"B-4, IDA,","city":"HYDERABAD, TELANGANA.","supplier":"VIRUPAKSHA ORGANICS","supplierCountry":"INDIA","foreign_port":"HO CHI MINH CITY","customer":"PYMEPHARCO HCMMC BRANCH","customerCountry":"VIETNAM","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"493.3","totalValueFC":"480","currency":"USD","unitRateINR":35736,"date":"15-Apr-2021","totalValueINR":"35736","totalValueInUsd":"480","indian_port":"ARSHIYA-SEZ\/PANVEL","hs_no":"29349990","bill_no":"4001159","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"VIETNAM, DEMOCRA","selfForZScoreResived":"Pharma Grade","supplierPort":"ARSHIYA-SEZ\/PANVEL","supplierAddress":"B-4, IDA,, HYDERABAD, TELANGANA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"SOFOSBUVIR","year":"2021","qtr":"Q2","strtotime":1619375400,"product":"SOFOSBUVIR","address":"PLOT NO.131,3RD FLOOR,NARMADAARCADE,SNEHAPURI COLONY,NACHARAM,","city":"HYDERABAD. AP","supplier":"OPTIMUS DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"LAHORE","customer":"MEEZAN BANK LTD","customerCountry":"PAKISTAN","quantity":"150.00","actualQuantity":"150","unit":"KGS","unitRateFc":"668.4","totalValueFC":"97025.5","currency":"USD","unitRateINR":48156.386666666665,"date":"26-Apr-2021","totalValueINR":"7223458","totalValueInUsd":"97025.5","indian_port":"HYDERABAD AIR","hs_no":"29141990","bill_no":"1374224","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.131,3RD FLOOR,NARMADAARCADE,SNEHAPURI COLONY,NACHARAM,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1624041000,"product":"SOFOSBUVIR","address":"PLOT NO.131,3RD FLOOR,NARMADAARCADE,SNEHAPURI COLONY,NACHARAM,","city":"HYDERABAD. AP","supplier":"OPTIMUS DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"KARACHI -","customer":"ALBARAKA BANK PAKISTAN ","customerCountry":"PAKISTAN","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"736.6","totalValueFC":"2164.8","currency":"USD","unitRateINR":53070.833333333336,"date":"19-Jun-2021","totalValueINR":"159212.5","totalValueInUsd":"2164.8","indian_port":"HYDERABAD AIR","hs_no":"29141990","bill_no":"2528803","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.131,3RD FLOOR,NARMADAARCADE,SNEHAPURI COLONY,NACHARAM,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1625423400,"product":"SOFOSBUVIR","address":"PLOT NO.131,3RD FLOOR,NARMADAARCADE,SNEHAPURI COLONY,NACHARAM,","city":"HYDERABAD. AP","supplier":"OPTIMUS DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"LAHORE","customer":"M\/S. ORDER OF MEEZAN BANK LTD.","customerCountry":"PAKISTAN","quantity":"150.00","actualQuantity":"150","unit":"KGS","unitRateFc":"650","totalValueFC":"95817.9","currency":"USD","unitRateINR":47606.666666666664,"date":"05-Jul-2021","totalValueINR":"7141000","totalValueInUsd":"95817.9","indian_port":"HYDERABAD AIR","hs_no":"29141990","bill_no":"2903019","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.131,3RD FLOOR,NARMADAARCADE,SNEHAPURI COLONY,NACHARAM,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1638124200,"product":"SOFOSBUVIR","address":"PLOT NO.131,3RD FLOOR,NARMADAARCADE,SNEHAPURI COLONY,NACHARAM,","city":"HYDERABAD. AP","supplier":"OPTIMUS DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"LAHORE","customer":"M\/S. TO THE ORDER OF","customerCountry":"PAKISTAN","quantity":"150.00","actualQuantity":"150","unit":"KGS","unitRateFc":"650","totalValueFC":"95647.6","currency":"USD","unitRateINR":47486.666666666664,"date":"29-Nov-2021","totalValueINR":"7123000","totalValueInUsd":"95647.6","indian_port":"HYDERABAD AIR","hs_no":"29141990","bill_no":"6362347","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.131,3RD FLOOR,NARMADAARCADE,SNEHAPURI COLONY,NACHARAM,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1643308200,"product":"SOFOSBUVIR","address":"B-4, IDA,","city":"HYDERABAD, TELANGANA.","supplier":"VIRUPAKSHA ORGANICS","supplierCountry":"INDIA","foreign_port":"KARACHI","customer":"HILTON PHARMA (PVT)LTD.","customerCountry":"PAKISTAN","quantity":"200.00","actualQuantity":"200","unit":"KGS","unitRateFc":"698.1","totalValueFC":"137935.6","currency":"USD","unitRateINR":51376.480000000003,"date":"28-Jan-2022","totalValueINR":"10275296","totalValueInUsd":"137935.6","indian_port":"ARSHIYA-SEZ\/PANVEL","hs_no":"29349990","bill_no":"4000297","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"ARSHIYA-SEZ\/PANVEL","supplierAddress":"B-4, IDA,, HYDERABAD, TELANGANA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1676831400,"product":"SOFOSBUVIR (FORM I)","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"YANGON","customer":"ALIDAC HEALTHCARE MYANMAR ","customerCountry":"MYANMAR","quantity":"140.00","actualQuantity":"140","unit":"KGS","unitRateFc":"955.8","totalValueFC":"132558.4","currency":"USD","unitRateINR":78200,"date":"20-Feb-2023","totalValueINR":"10948000","totalValueInUsd":"132558.4","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"7920440","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MYANMAR","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689705000,"product":"SOFOSBUVIR, BATCH NO : ASOBC23009 MFG DA","address":"HOUSE NO. 1376\/241, ASHIRWAD BHAWAN KUMBHARPURA, GANDHIBAGH","city":"NAGPUR","supplier":"ARKOS CORPORATION","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"TO THE ORDER OF","customerCountry":"BANGLADESH","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"2300","totalValueFC":"8869.7","currency":"USD","unitRateINR":182250.02249999999,"date":"19-Jul-2023","totalValueINR":"729000.09","totalValueInUsd":"8869.7","indian_port":"AHMEDABAD AIR","hs_no":"29335990","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"HOUSE NO. 1376\/241, ASHIRWAD BHAWAN KUMBHARPURA, GANDHIBAGH, NAGPUR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695234600,"product":"SOFOSBUVIR","address":"564\/A\/22, ROAD NO.92","city":"HYDERABAD,ANDHRA PRADESH","supplier":"VIATRIS","supplierCountry":"INDIA","foreign_port":"ISLAMABAD - ISLAMABA","customer":"MEEZAN BANK LIMITED","customerCountry":"PAKISTAN","quantity":"155.00","actualQuantity":"155","unit":"KGS","unitRateFc":"770","totalValueFC":"117566.7","currency":"USD","unitRateINR":62961.290322580644,"date":"21-Sep-2023","totalValueINR":"9759000","totalValueInUsd":"117566.7","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"4073095","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"564\/A\/22, ROAD NO.92, HYDERABAD,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1711909800,"product":"SOFOSBUVIR","address":"564\/A\/22, ROAD NO.92","city":"HYDERABAD,ANDHRA PRADESH","supplier":"VIATRIS","supplierCountry":"INDIA","foreign_port":"ISLAMABAD - ISLAMABA","customer":"MEEZAN BANK LIMITED","customerCountry":"PAKISTAN","quantity":"240.00","actualQuantity":"240","unit":"KGS","unitRateFc":"770","totalValueFC":"180801.2","currency":"USD","unitRateINR":62909.25,"date":"01-Apr-2024","totalValueINR":"15098220","totalValueInUsd":"180801.2","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"8805599","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"564\/A\/22, ROAD NO.92, HYDERABAD,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1659119400,"product":"SOFOSBUVIR BATCH NO.:RD-SFB(FORM VI)-202204081 MFG DATE: APR.08, 2022 EXP DATE:APR.08, 2024(AS PER ADVANCE LIC)","address":"A-202, 2ND FLOOR, MONDEAL SQUARE BLDG,VEJALPUR:OPP:KARANAVATI CLUB,","city":"S.G. HIGH WAY,AHMEDABAD, GUJARAT.","supplier":"CHANGZHOU PHARMACEUTICAL FACTORY","supplierCountry":"CHINA","foreign_port":"NA","customer":"MEDWISE OVERSEAS PRIVATE ","customerCountry":"INDIA","quantity":"11.30","actualQuantity":"11.3","unit":"KGS","unitRateFc":"760","totalValueFC":"8742.8","currency":"USD","unitRateINR":"61522","date":"30-Jul-2022","totalValueINR":"695198.6","totalValueInUsd":"8742.8","indian_port":"AHMEDABAD AIR","hs_no":"29349990","bill_no":"9799958","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"A-202, 2ND FLOOR, MONDEAL SQUARE BLDG,VEJALPUR:OPP:KARANAVATI CLUB,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1659983400,"product":"SOFOSBUVIR","address":"1017\/1018, CORPORATE AVENUE,,SONAW ALA ROAD,GOREGAON EAST,","city":"MUMBAI MAHARASHTRA,MAHARASHTRA","supplier":"ALARIS PHARMACEUTICALS PTE ","supplierCountry":"CHINA","foreign_port":"NA","customer":"BIOPHARMA","customerCountry":"INDIA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"690","totalValueFC":"3479.6","currency":"USD","unitRateINR":"55372.5","date":"09-Aug-2022","totalValueINR":"276862.5","totalValueInUsd":"3479.6","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"9937312","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"1017\/1018, CORPORATE AVENUE,,SONAW ALA ROAD,GOREGAON EAST,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1671042600,"product":"SOFOSBUVIR (CAS NO : 1190307-88-0)","address":"1017\/1018, CORPORATE AVENUE,,SONAW ALA ROAD,GOREGAON EAST,","city":"MUMBAI MAHARASHTRA,MAHARASHTRA","supplier":"ALARIS PHARMACEUTICALS PTE ","supplierCountry":"CHINA","foreign_port":"NA","customer":"BIOPHARMA","customerCountry":"INDIA","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"721","totalValueFC":"17936.1","currency":"USD","unitRateINR":"59122","date":"15-Dec-2022","totalValueINR":"1478050","totalValueInUsd":"17936.1","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"3760085","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"1017\/1018, CORPORATE AVENUE,,SONAW ALA ROAD,GOREGAON EAST,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1673893800,"product":"PHARMACEUTICALS RAW MATERIAL FOR MFG OF INTERMEDIATE BULK DRUG-SOFOSBUVIR","address":"B-4, IDA,","city":"HYDERABAD, TELANGANA.","supplier":"HANGZHOU QICHUANG CHEMICAL","supplierCountry":"CHINA","foreign_port":"N\/A","customer":"VIRUPAKSHA ORGANICS","customerCountry":"INDIA","quantity":"100.00","actualQuantity":"100","unit":"KGS","unitRateFc":"600","totalValueFC":"61424.1","currency":"USD","unitRateINR":"50220","date":"17-Jan-2023","totalValueINR":"5022000","totalValueInUsd":"61424.1","indian_port":"ARSHIYA-SEZ\/PANVEL","hs_no":"29349990","bill_no":"1000981","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"ROOM 1204, NINGBO MANSION, NO. 46, TIANMUSHAN ROAD, XIHU DISTRICT, ZHE JIANG Hangzhou - 310007, CHINA CHINA","customerAddress":"B-4, IDA,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1676831400,"product":"PHARMACEUTICALS RAW MATERIAL FOR MFG OFINTERMEDIATE BULK DRUG-SOFOSBUVIR","address":"B-4, IDA,","city":"HYDERABAD, TELANGANA.","supplier":"HANGZHOU QICHUANG CHEMICAL CO, LTD","supplierCountry":"CHINA","foreign_port":"N\/A","customer":"VIRUPAKSHA ORGANICS","customerCountry":"INDIA","quantity":"120.00","actualQuantity":"120","unit":"KGS","unitRateFc":"605.8","totalValueFC":"73633","currency":"USD","unitRateINR":"50678","date":"20-Feb-2023","totalValueINR":"6081355","totalValueInUsd":"73633","indian_port":"ARSHIYA-SEZ\/PANVEL","hs_no":"29349990","bill_no":"1003142","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"N\/A","customerAddress":"B-4, IDA,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1686508200,"product":"SOFOSBUVIR (CAS NO - 1190307-88-0)","address":"1017\/1018, CORPORATE AVENUE,,SONAW ALA ROAD,GOREGAON EAST,","city":"MUMBAI MAHARASHTRA,MAHARASHTRA","supplier":"ALARIS PHARMACEUTICALS PTE ","supplierCountry":"CHINA","foreign_port":"NA","customer":"BIOPHARMA","customerCountry":"INDIA","quantity":"69.00","actualQuantity":"69","unit":"KGS","unitRateFc":"600","totalValueFC":"42006.3","currency":"USD","unitRateINR":"50040","date":"12-Jun-2023","totalValueINR":"3452760.01","totalValueInUsd":"42006.3","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"1017\/1018, CORPORATE AVENUE,,SONAW ALA ROAD,GOREGAON EAST,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690137000,"product":"PHARMACEUTICALS RAW MATERIAL FOR MFG OF INTERMEDIATE BULK DRUG - SOFOSBUVIR (CAS: 1190307-88-0 )","address":"B-4, IDA,","city":"HYDERABAD, TELANGANA.","supplier":"HIGHPHARM MEDCHEM CO. ","supplierCountry":"CHINA","foreign_port":"N\/A","customer":"VIRUPAKSHA ORGANICS","customerCountry":"INDIA","quantity":"40.00","actualQuantity":"40","unit":"KGS","unitRateFc":"625","totalValueFC":"25231.3","currency":"USD","unitRateINR":"51843.8","date":"24-Jul-2023","totalValueINR":"2073750","totalValueInUsd":"25231.3","indian_port":"ARSHIYA-SEZ\/PANVEL","hs_no":"29349990","bill_no":"1012755","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"WEST OF 2F,NO.800 CHUANGYUAN ROAD, HI-TECH ZONE,NINGBO, CHINA","customerAddress":"B-4, IDA,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695580200,"product":"PHARMACEUTICAL RAW MATERIAL FOR MFG OF INTERMEDIATE BULK DRUG- SOFOSBUVIR CAS NO.1190307-88-0","address":"B-4, IDA,","city":"HYDERABAD, TELANGANA.","supplier":"HANGZHOU QICHUANG CHEMICAL","supplierCountry":"CHINA","foreign_port":"N\/A","customer":"VIRUPAKSHA ORGANICS","customerCountry":"INDIA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"750","totalValueFC":"2278.2","currency":"USD","unitRateINR":"63037.7","date":"25-Sep-2023","totalValueINR":"189113","totalValueInUsd":"2278.2","indian_port":"ARSHIYA-SEZ\/PANVEL","hs_no":"29349990","bill_no":"1016727","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"ROOM 1204, NO.46 TIANMUSHAN ROAD, X IHU DISTRICT, HANGZHOU, CHINA CHINA","customerAddress":"B-4, IDA,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717957800,"product":"SOFOSBUVIR (CAS: 1190307-88-0)","address":"VILLAGE NAG KALAN,MAJITHA ROAD,MAJ","city":"AMRITSAR,PUNJAB","supplier":"M\/S. QUANZHOU FORTUNE BIOPHARMA CO.LTD","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"KWALITY PHARMACEUTICALS","customerCountry":"INDIA","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"650","totalValueFC":"3938.3","currency":"USD","unitRateINR":"54795","date":"10-Jun-2024","totalValueINR":"328770","totalValueInUsd":"3938.3","indian_port":"Delhi Air","hs_no":"29339990","bill_no":"3913551","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"ADD: ROOM 2603 RONG TAI\\'AN BUILDINGNO. 139 JINHUAI STREET FENGZE ROADFENGZE DISTRICT QUANZHOU CITY FUJIA CHINA","customerAddress":"VILLAGE NAG KALAN,MAJITHA ROAD,MAJ"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1721241000,"product":"SOFOSBUVIR BATCH NO.: SFB(FORM VI)-702-240603","address":"A-202, 2ND FLOOR, MONDEAL SQUARE","city":"S.G. HIGH WAY,AHMEDABAD, GUJARAT.","supplier":"CHANGZHOU PHARMACEUTICAL FACTORY","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"MEDWISE OVERSEAS PRIVATE ","customerCountry":"INDIA","quantity":"23.72","actualQuantity":"23.72","unit":"KGS","unitRateFc":"600","totalValueFC":"14378.2","currency":"USD","unitRateINR":"50670","date":"18-Jul-2024","totalValueINR":"1201892.4","totalValueInUsd":"14378.2","indian_port":"Ahmedabad Air","hs_no":"29349990","bill_no":"4579768","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"NO.518 LAODONG EAST ROAD, CHANGZHOU, JIANGSU PROVINCE CHINASDNF CHINA","customerAddress":"A-202, 2ND FLOOR, MONDEAL SQUARE"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1721845800,"product":"SOFOSBUVIR BATCH NO.: SFB(FORM VI)-702-240603","address":"A-202, 2ND FLOOR, MONDEAL SQUARE","city":"S.G. HIGH WAY,AHMEDABAD, GUJARAT.","supplier":"CHANGZHOU PHARMACEUTICAL FACTORY","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"MEDWISE OVERSEAS PRIVATE ","customerCountry":"INDIA","quantity":"5.75","actualQuantity":"5.75","unit":"KGS","unitRateFc":"600","totalValueFC":"3489.6","currency":"USD","unitRateINR":"50730","date":"25-Jul-2024","totalValueINR":"291697.5","totalValueInUsd":"3489.6","indian_port":"Ahmedabad Air","hs_no":"29349990","bill_no":"4693391","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"NO.518 LAODONG EAST ROAD, CHANGZHOU, JIANGSU PROVINCE CHINASDNF CHINA","customerAddress":"A-202, 2ND FLOOR, MONDEAL SQUARE"}]